News | June 29, 2009

Cordex Completes Production of ATPace Drug Clinical Trial

June 29, 2009 – Cordex Pharma said today it successfully completed the production of the ATPace clinical trial material (CTM) in preparation for planned pivotal clinical trials. ATPace is a novel, proprietary, stable, injectable formulation of adenosine 5'-triphosphate (ATP) under development as a therapeutic and diagnostic drug for the management of cardiac arrhythmias, said the company.
The protocol of these clinical trials has been approved by the FDA under the special protocol assessment process.

A stable liquid formulation of ATP is a prerequisite for ATPace's clinical superiority over adenosine, the only approved competition in the United States. The maintenance of intact ATP molecules in solution is critical for the unique bradycardic effects of ATP, in particular its blockade of atrio-ventricular nodal conduction, the company said. Cordex has filed a formulation patent covering this stable liquid formulation of ATP for intravenous administration.

The ATPace CTM was produced offsite by a U.S. manufacturer of sterile injectable products under the regulatory supervision of Cordex and Cato Research Inc. The CTM will be used in the planned clinical trials for the acute treatment of patients presenting with paroxysmal supraventricular tachycardia (PSVT) in the emergency room.

Several formulations of ATP have been used in Europe for more than five decades as the drug of choice for the acute conversion of PSVT to normal sinus rhythm. During this extended period of use, ATP manifested an excellent safety and efficacy profile. Cordex intends to use clinical data obtained in Europe as a part of the ATPace's NDA under section 505b(2).

For more information: www.cordexpharma.com

Related Content

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Overlay Init